Patents Examined by Tracy Vivlemore
  • Device for concentration and separation of circulating tumor cells, and method for concentration and separation of circulating tumor cells
    Patent number: 11221325
    Abstract: To provide a device for concentration and separation of circulating tumor cells, capable of recovering circulating tumor cells in a blood-derived specimen simply, at a high recovery rate, and with low invasion of the tumor cells. A device for concentration and separation of circulating tumor cells present in a blood-derived specimen, in which a cell separating agent with thixotropic property having a specific gravity ranging from 1.050 to 1.080 and enabling the separation of tumor cells and blood cells other than the tumor cells by a centrifugal operation is housed in a bottomed tube-shaped container closed at one end and opened at the other end.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 11, 2022
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Ryusuke Okamoto, Tomonori Inoue
  • Methods for treating periodontal diseases
    Patent number: 11214840
    Abstract: Provided herein are aptamers that bind specifically to the surface proteins of periodontal pathogens. Also provided herein are methods for detecting and treating periodontal disease in a subject. The method comprises detecting bacteria associated with periodontal disease by use of the present aptamers to analyze a sample taken from a gum pocket of a tooth of the subject; and treating the periodontal disease of the subject by administering to the gum pocket of the tooth a bactericide or an anti-microbial phototherapy to eradicate the bacteria associated with periodontal disease.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: January 4, 2022
    Assignee: NATIONAL CHENG KUNG UNIVERSITY
    Inventors: Ping-Ching Wu, Dar-Bin Shieh, Fong-Yu Cheng, Yuh-Ling Chen
  • Cyclohexyl benzamide compounds
    Patent number: 11214562
    Abstract: A compound of the Formula (1) is below provided where R1-R5 are as described in the description and each “*” represents a chiral center.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: January 4, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Zhi Long Hu, Lian Zhu Liu, Tianwei Ma, Mi Zeng, Haizhen Zhang
  • Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
    Patent number: 11214574
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: January 4, 2022
    Assignee: Prelude Therapeutics, Incorporated
    Inventors: Juan Luengo, Hong Lin, Michael Hawkins, Rupa Shetty, Philip Pitis, Gisela Saborit Villarroya
  • TGF-beta oligonucleotide for use in treatment of ophthalmic diseases
    Patent number: 11207341
    Abstract: The present invention is directed to an oligonucleotide comprising a nucleic acid sequence of SEQ ID No. 1 or parts thereof, wherein 1 to 4 nucleotides at the 3?-end and/or at the 5?-end of the oligonucleotide are modified at a base, a sugar and/or a phosphate for use in a method of reducing or inhibiting of scarring, of fibrotic closure of the trabeculectomy canal, of epithelial-to-mesenchymal transition of the trabecular meshwork and/or providing of protecting activity of the optic nerve optionally the optic nerve head. Further, the present invention refers to a pharmaceutical composition comprising such oligonucleotide and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: December 28, 2021
    Assignee: ISARNA THERAPEUTICS GMBH
    Inventors: Eugen Leo, Michel Janicot, Katja Wosikowski-Buters, Petra Fettes
  • High density lipoprotein binding protein (Hdlbp/Vigilin) iRNA compositions and methods of use thereof
    Patent number: 11207342
    Abstract: The invention relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting a High Density Lipoprotein Binding Protein (Hdlbp/Vigilin) gene, as well as methods of inhibiting expression of Hdlbp/Vigilin and methods of treating subjects having a disorder of lipid metabolism, such as mixed hyperlipidemia, hypertriglyceridemia or hypercholesterolemia, using such dsRNA agents and compositions.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: December 28, 2021
    Assignees: Alnylam Pharmaceuticals, Inc., ETH Zurich
    Inventors: Muthiah Manoharan, Markus Stoffel, Mehrpouya Balaghy Mobin
  • Increasing RNAi efficiency through single nucleotide mismatches
    Patent number: 11208653
    Abstract: Methods and compositions for increasing RNAi efficiency through single nucleotide mismatches.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: December 28, 2021
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Grace Chen, David Bartel, Hazel Sive
  • Selective inhibitors of protein arginine methytransterase 5 (PRMT5)
    Patent number: 11208416
    Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: December 28, 2021
    Assignee: Prelude Therapeutics Incorporated
    Inventors: Hong Lin, Juan Luengo, Rupa Shetty, Michael Hawkins
  • Compositions and methods for reducing cell viability
    Patent number: 11208389
    Abstract: This invention is directed to compositions, methods and kits that can be used for reducing cell viability, inducing cell apoptosis, and inhibiting cell proliferation, such as for the treatment of cancer. The invention is also directed to compositions, methods and kits that can be used for treating inflammatory conditions, such as by modulating inflammatory cytokines.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: December 28, 2021
    Assignee: GLAX LLC
    Inventors: Rakesh K Srivastava, Sharmila Shankar, Sushant Kumar Shrivastava, Anupam G. Banerjee
  • Post-selex modification methods
    Patent number: 11208663
    Abstract: Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: December 28, 2021
    Assignee: SomaLogic, Inc.
    Inventors: Thale C. Jarvis, John C. Rohloff, Amy D. Gelinas, Chi Zhang, Daniel W. Drolet, Sheela M. Waugh, Nebojsa Janjic
  • Modulators of IRF5 expression
    Patent number: 11208650
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting IRF5 expression, which may be useful for treating, preventing, or ameliorating a disease associated with IRF5.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: December 28, 2021
    Assignee: IONIS PHARMACEUTICALS, INC.
    Inventor: Susan M. Freier
  • Reagents and methods for detecting protein lysine 2-hydroxyisobutyrylation
    Patent number: 11204353
    Abstract: The invention provides an isolated peptide comprising a lysine 2-hydroxyisobutyrylation site, a lysine 2-hydroxyisobutyrylation specific affinity reagent that specifically binds to the peptide, and a method for detecting protein lysine 2-hydroxyisobutyrylation in a sample using the reagent.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: December 21, 2021
    Assignee: PTM Biolab Inc.
    Inventors: Yingming Zhao, Lunzhi Dai
  • Method of controlled competitive exchange
    Patent number: 11202835
    Abstract: The present invention relates to a method of controlled competitive exchange of a first agent bound to a metal coordination complex with a competing agent, with selection of the nature of the first agent allowing a tailoring of the binding strength and thereby allowing for a desired level of control for subsequent displacement by the selected competing agent. The method may be employed for release of therapeutic agents, sequestration of larger molecules from a sample, generation of a preferred binding surface and the like.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: December 21, 2021
    Assignee: ANTEO TECHNOLOGIES PTY LTD
    Inventors: Chang-Yi Huang, Nobuyoshi Joe Maeji
  • Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
    Patent number: 11203593
    Abstract: This present invention relates to forms of methyl {4.6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3.4-b]pyridino-3-yl]pyrimidino-5-yl}methylcarbamate comprising its Modification I. Modification II. mono-DMSO solvate. sesqui-DMSO solvate and ¼-ethyl acetate solvate.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: December 21, 2021
    Assignee: Adverio Pharma GmbH
    Inventors: Birgit Keil, Franz-Josef Mais, Winfried Joentgen, Alfons Grunenberg
  • Formulations for treatment of dry eye disease
    Patent number: 11197821
    Abstract: The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: December 14, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: David Clark, Todd Brady, Susan Macdonald, Stephen Gitu Machatha
  • Tetrahydronaphthyridinepentanamide integrin antagonists
    Patent number: 11192889
    Abstract: Tetrahydronaphthyridines of formula are disclosed. These compounds selectively inhibit ?V?3 without activating the ?V?3 receptor. They are useful for treating osteoporosis, acute myelogenous leukemia, sickle cell disease, focal segmental glomerulosclerosis, fibrosis, supravalvular aortic stenosis associated with Williams syndrome, tumors expressing ?V?3, tumor metastasis, bone resorption, T-cell lymphoma, retinal disease, age-related macular degeneration, diabetic retinitis, and herpes simplex virus infection. They may also be used for inhibiting tumor angiogenesis.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: December 7, 2021
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Barry S. Coller, Marta Filizola, Michael Andrew Foley
  • 17?-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
    Patent number: 11180757
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the HSD17B13 gene, as well as methods of inhibiting expression of HSD17B13, and methods of treating subjects that would benefit from reduction in expression of HSD17B13, such as subjects having a HSD17B13-associated disease, disorder, or condition, using such dsRNA compositions.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: November 23, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Frederic Tremblay, Noura S. Abul-Husn, Omri Gottesman, Alexander Li, Xiping Cheng, Yurong Xin, Jesper Gromada, Frederick E. Dewey, Aris Baras, Alan Shuldiner, Stuart Milstein
  • PLXDC2 ligands
    Patent number: 11180473
    Abstract: Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: November 23, 2021
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas, Nuria Tubau-Juni
  • Compositions and methods for hemoglobin production
    Patent number: 11179379
    Abstract: Methods and compositions for producing fetal hemoglobin and treating a hemoglobinopathy or thalassemia are disclosed.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: November 23, 2021
    Assignees: THE CHILDREN'S HOSPITAL OF PHILADELPHIA, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, COLD SPRING HARBOR LABORATORY
    Inventors: Gerd Blobel, Jeremy Grevet, Junwei Shi, Christopher Vakoc
  • Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
    Patent number: 11180759
    Abstract: The invention relates to the inhibition of expression of mutant KRAS sequences using RNA interference, antisense oligonucleotides, and chemically-modified oligonucleotides.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: November 23, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Chad Pecot, Salma H. Azam